FDA Panel Will Review Cardiac Resynch ICD For Mortality Reduction Claim
This article was originally published in The Gray Sheet
Executive Summary
An expanded labeling proposal facing FDA Circulatory System Devices Panel review July 28 would claim a 36% risk reduction in all-cause mortality for patients with Guidant's cardiac resynchronization therapy defibrillator (CRT-D)
You may also be interested in...
Over-The-Counter Defibrillator, AED Adverse Events To Be Gauged By Panel
FDA panel recommendations at a July 29 meeting to consider an OTC indication for an automated external defibrillator will affect only the product under review. Manufacturers of other approved systems will have to file data separately with CDRH to earn over-the-counter status, according to the agency
Over-The-Counter Defibrillator, AED Adverse Events To Be Gauged By Panel
FDA panel recommendations at a July 29 meeting to consider an OTC indication for an automated external defibrillator will affect only the product under review. Manufacturers of other approved systems will have to file data separately with CDRH to earn over-the-counter status, according to the agency
Defibrillator Coverage Decision Will Weigh DEFINITE, COMPANION Trials
St. Jude Medical estimates the worldwide market for high-voltage cardiac rhythm management devices will approach $4.7 bil. by year-end, growing 20% over the 2003 level, based on published peer-reviewed studies and a potentially broader Medicare coverage policy